Table 1

Patient characteristics and immunogenicity before and after COVID-19

Patient number	1	2	3	4	5	6	7
Patient characteristics
Age (years)	67	55	44	45	57	58	60
Gender	Female	Male	Male	Female	Male	Female	Male
Diagnosis	RA	RA	RA	IgG4	MPA	GPA	EGPA
Immunosuppressive therapy	RTX	RTX, MTX	RTX, MTX	RTX	RTX, Pred, HCQ	RTX, Pred, AZT	RTX, MTX
Months from last RTX to infection	8	6	12	10	7	7	11
Further risk factors	Age	BMI=32	COPD, BMI=34	DM2, HT, BMI=50, OSA, 40 py	HT, BMI=33, 40 py	HT, BMI=30	CNI, stroke, hemiparesis
Vaccinations
Vaccinations before infection	4	4	4	5	3	4	4
Last vaccination to infection (days)	29	35	19	6	36	25	30
B cells status
Assessment to infection (days)	0	35	19	6	36	25	30
CD19 positive cells (cells/nl)	0.02	0.00	0.00	0.02	0.00	0.00	0.00
Immunogenicity before/after infection
Assessment before/after infection (days)	0/70	4/28	19/27	6/22	8/20	25/30	2/57
Neutralisation capacity (%)	13.4/0	0/0	12.4/0	14.2/99.5	22.9/18.7	0/0	0/24.2
IgG against RBD (BAU/ml)†	0/12.4	0/0	2.3/0	139/2845	1.7/2.0	0/5.2	5.2/31.6
IgG against spike protein (BAU/ml)†	0/1.6	0/0	2.1/44.7	39.7/1928	0/3.6	0/10.8	59.5/310
T cell response (mIU/ml)	n.a./182*	n.a./858	357/982	40/85	0/328*	n.a./n.a.	474/930
Infection
Date of positive PCR	07 December 2021	14 January 2022	22 January 2022	27January 2022	08 February 2022	08 February 2022	13 February 2022
Omicron prevalence at infection (%)	<1	84; Omicron proven	94	94	99	99	99
Symptoms of COVID-19	Cough, joint pain	Cough, fever, headache, limb and joint pain	Sore throat, headache, shivering	Cough, sore throat, headache, limb pain, fatigue	Cough, headache, shivering, decreased taste/smell	None	Cough, rhinitis, headache, fever
Medication for COVID-19	None	Ibuprofene, clarithromycine	None	None	Acetylsalicylic acid	None	Acetaminophene
WHO rating scale (0 to 10)‡	2	2	2	2	2	1	2

Lower limit of normal for B cells: 0.1 /nl; positive immunogenicity test results in bold letters: >30% for neutralisation capacity, >1 S/CO for IgG which corresponds to >64.2 BAU/ml against RBD and >58.6 BAU/ml against spike protein, >200 mIU/ml=positive and >100 mIU/ml=borderline positive or >135 mIU/ml=positive in case of negative controls <100 mIU/ml for T cell response.
*Low response to mitogen positive control.
†Converted from semiquantitative S/CO values by conversion formula supplied by manufacturer.
‡According to Marshall et al.6
AZT, azathioprine; BMI, body mass index in (kg/m²); CD, cluster of differentiation; CNI, chronic renal insufficiency; COPD, chronic obstructive pulmonary disease; DM2, diabetes mellitus type II; (E)GPA, (eosinophilic) granulomatosis with polyangiitis; HCQ, hydroxychloroquine; HT, hypertension; IgG, immunoglobulin G; IgG4, immunoglobulin-4-associated disease; MPA, microscopic polyangiitis; MTX, methotrexate; n.a., test result not available; OSA, obstructive sleep apnoea; Pred, prednisolone; py, pack years of smoking; RA, rheumatoid arthritis; RBD, receptor binding domain; RTX, rituximab;